As a matter of fact, both in vitro and in vivo studies have shown that treatment of highly metastatic human triple-negative breast cancer (TNBC) (MDA-MB-231 and MDA-MB-436 cell lines) with Apigenin interferes with YAP/TAZ-transcriptional enhanced associate domain (TEADs) molecular interactions (as confirmed by monitoring the transcription levels of connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61)—two YAP/TAZ-dependent genes—that in turn inhibited the stemness characteristics of cancer [69]. Here, CCN1 is linked to triple-negative breast carcinoma.